Will There Be A Cure For Herpes in 2025?

This article covers the state of herpes research as of early 2025.

For the most up-to-date overview of vaccine candidates and clinical trial progress, see our 2026 herpes cure and vaccine update. The year 2025 was seen as a pivotal moment for herpes research due to several promising clinical trials and advancements in diagnostic technologies.While a confirmed cure has not yet emerged, advancements in gene editing and therapeutic vaccines generated significant optimism throughout the year.

HSV infections can lead to recurrent, painful genital lesions (genital ulcer disease), increased risk of HIV acquisition and transmission, and neonatal herpes, which has a high fatality rate. HSV-1 can also cause serious complications, including neurological, corneal, and mucocutaneous conditions.

Current treatments manage symptoms but do not offer a cure. The main challenge lies in targeting the latent virus and ensuring the immune system can effectively eliminate it, though significant advancements in research have brought hope closer than ever.

Recent Research Developments

Researchers at Fred Hutch Cancer Center have developed an experimental gene-editing therapy that has shown remarkable success in preclinical studies.Using a "molecular scissors" approach, this therapy targets and damages HSV DNA, reducing the virus by over 90% in lab mice.

It also decreases viral shedding, potentially lowering transmission risks.While these results are groundbreaking, human clinical trials are still in preparation stages, making it unlikely that this therapy will be widely available in 2025.

A Vaccine for Herpes May Be Close

Pharmaceutical companies like Moderna and BioNTech are conducting early-stage clinical trials for HSV vaccines. Moderna's mRNA-1608 vaccine, targeting HSV-2, was in Phase 1/2 trials with a projected completion date of April 2025.

As of mid-2026, full results from this trial have not yet been published; for the latest status see our 2026 herpes vaccine update.

This vaccine aims to induce a strong immune response by combining neutralizing antibodies and cell-mediated immunity, potentially providing cross-protection against HSV-1 and preventing both genital lesions and viral latency in the dorsal root ganglia.

Meanwhile, BioNTech's BNT163 vaccine, in Phase 1 trials, encodes three HSV-2 glycoproteins designed to block viral entry and counteract its immunosuppressive properties.

Historically, developing effective vaccines has been challenging due to the virus's ability to persist in the body and evade immune responses.

A $35 Billion Global Issue

Approximately 67% of the world's population aged 0-49 years are infected with HSV-1.

HSV-1 is typically acquired orally in childhood and can cause oral herpes (cold sores).

Around 13% of the world's population aged 15-49 years are living with HSV-2.

HSV-2 is primarily transmitted through sexual contact and causes genital herpes.

In total, nearly 846 million individuals globally are estimated to be living with genital herpes (both HSV-1 and HSV-2), highlighting the widespread nature of this infection.

A study published in BMC Global and Public Health estimated the global economic burden of genital HSV-2 and HSV-1 infections to be $35.3 billion in 2016, with genital HSV-2 alone accounting for about $31.2 billion of this total.Current estimates suggest that even conservative treatment approaches incur costs upwards of $16.5 billion annually due to symptomatic episodes and ongoing medical care for HSV-2 infections.

In the meantime, managing outbreaks through diet and lifestyle changes and natural remedies remains the most accessible approach for the majority of people living with HSV.